

Regular Meeting of the

## Santa Clara County Health Authority Pharmacy & Therapeutics Committee

Thursday, June 16, 2022, 6:00 PM – 8:00 PM

Santa Clara Family Health Plan

6201 San Ignacio Ave, San Jose, CA 95119

# Minutes (Open) - Approved

### Members Present

Jimmy Lin, MD, Chair  
Ali Alkoraishi, MD  
Dang Huynh, PharmD, Director of Pharmacy and UM  
Laurie Nakahira, DO, Chief Medical Officer  
Jesse Parashar-Rokicki, MD  
Judy Ngo, PharmD

### Staff Present

Duyen Nguyen, PharmD, Clinical Pharmacist  
Caroline Tambe, PharmD, Clinical Pharmacist  
Jennifer Koh, Pharmacy Resident  
Amy O'Brien, Administrative Assistant  
Robyn Esparza, Administrative Assista

### Members Absent

Dolly Goel, MD  
Peter Nguyen, DO  
Xuan Cung, PharmD

#### 1. Roll Call

Jimmy Lin, MD, Chair, called the meeting to order at 6:05 pm. Roll call was taken and a quorum was established.

#### 2. Public Comment

There were no public comments.

#### 3. Open Meeting Minutes

The 1Q 2022 P&T Committee open meeting minutes were reviewed.

**It was moved, seconded and the open minutes of the 1Q 2022 P&T meeting minutes were unanimously approved.**

**Motion:** Dr. Nakahira

**Second:** Dr. Alkoraishi,

**Ayes:** Dr. Alkoraishi, Dr. Huynh, Dr. Lin, Dr. Nakahira, Dr. Ngo, Dr. Parashar-Rokicki

**Absent:** Dr. Cung, Dr. Goel, Dr. Nguyen

#### 4. Standing Agenda Items

##### a. Chief Medical Officer Health Plan Updates

Laurie Nakahira, D.O., Chief Medical Officer (CMO), presented the CMO Health Plan Updates.

The health plan membership for both Medi-Cal (MC) and Cal MediConnect (CMC) line of businesses combined reached over 300,000. She noted that once the Public Health Extension (PHE) ends, the membership will dip because there will be members dis-enrolled because of the re-eligibility process.

The DMHC Financial Audit is taking place. The audit examines the financial health and sustainability of the health plan.

There is another DMHC audit that will occur in October. The health plan is preparing for the NCQA interim audit for our MC line of business.

##### b. Medi-Cal (MC) Rx Update

Dang Huynh, PharmD, Director, Pharmacy and Utilization Management, provided an MC Rx Update.

Dr. Huynh noted that starting June 1, 2022, blood pressure monitors and cuffs are now a benefit for Medi-Cal Rx.

Dr. Huynh noted the DME Blood Pressure (BP) Monitoring Order Form to include what Medi-Cal Rx covers.

Dr. Huynh noted DHCS is going to delay the re-implementation of point-of-sale edits and prior authorization requirements. DHCS will use a step-wise approach instead of turning everything back on all at once.

##### c. Grievance & Appeal Reports – 4Q 2021 & 1Q 2022

Dang Huynh, PharmD, Director, Pharmacy and Utilization Management, reviewed the 4Q 2021 & 1Q 2022 Grievance & Appeal Reports. Dr. Huynh will follow-up with the G&A Department as to why Scopolamine was upheld and then follow-up with Dr. Lin directly.

##### d. Policy Review

- i. PH.10 Medicare Part D Transition (D-SNP)
- ii. PH.16 Medi-Cal Rx

Dr. Huynh reviewed the policies, PH.10 is due for annual review and PH.16 is new.

**It was moved, seconded and the SCFHP Pharmacy Policies were unanimously approved.**

**Motion:** Dr. Lin

**Second:** Dr. Nakahira

**Ayes:** Dr. Alkoraishi, Dr. Huynh, Dr. Lin, Dr. Nakahira, Dr. Ngo, Dr. Parashar-Rokicki,

**Absent:** Dr. Cung, Dr. Goel, Dr. Nguyen

##### e. Plan/Global Medi-Cal Drug Use Review

###### i. Annual DHCS Global DUR Submission

Caroline Tambe, PharmD, Clinical Pharmacist, presented the annual DHCS Global DUR Submission.

###### ii. Drug Utilization Evaluation Update

Dr. Tambe reviewed the results from SCFHP's quarterly retrospective Drug Use Evaluation (DUE) program. For Q1 2022, the focus was on cardiovascular disease. For Q2 2022, the plan did a provider mailing for polypharmacy.

##### f. Emergency Supply Report – 2Q 2021

Duyen Nguyen, PharmD, Clinical Pharmacist, reviewed the Emergency Supply Report for Q2 2022.

Dr. Nguyen reported in Q2 2022, SCFHP had a total of 20,413 ER visits, per claims and encounter data.

Approved claims were appropriate, and there were no inappropriately denied claims. Overall, there were no issues with the completed charts that were reviewed.

**g. NCQA Member Portal Evaluation**

Dr. Nguyen presented the NCQA Member Portal Evaluation and reviewed the results. Dr. Nguyen noted both accuracy and quality measures met goal at 100%. There were no deficiencies identified.

Dr. Nguyen noted that there was an update from the last quarter report. She noted that NCQA requested a comparison with the report. Compared with that report from August 2020, the accuracy continued to be 100%.

**Adjourned to Closed Session at 6:31p.m.  
Pursuant to Welfare and Institutions Code Section 14087.36 (w)**

**5. Closed Meeting Minutes**

The 1Q 2022 P&T Committee closed meeting minutes were reviewed.

**It was moved, seconded and the closed minutes of the 1Q 2022 P&T meeting minutes were unanimously approved.**

**Motion:** Dr. Huynh

**Second:** Dr. Parashar-Rokicki

**Ayes:** Dr. Alkoraishi, Dr. Huynh, Dr. Lin, Dr. Nakahira, Dr. Ngo, Dr. Parashar-Rokicki

**Absent:** Dr. Cung, Dr. Goel, Dr. Nguyen

**6. Metrics and Financial Updates**

**a. Membership Report**

Dr. Huynh presented the Membership Report.

**b. Pharmacy Dashboard**

Dr. Huynh reviewed the Pharmacy Dashboard.

**c. Drug Utilization & Spend – 1Q 2022**

Dr. Huynh presented the Drug Utilization & Spend for 1Q 2022.

**7. Discussion and Recommendations for Changes to SCFHP's Cal MediConnect Formulary & Coverage Determination Criteria**

**a. Pharmacy Benefit Manager 1Q 2022 P&T Minutes**

Dr. Huynh reviewed the Pharmacy Benefit Manager 1Q 2022 P&T Minutes.

**b. Pharmacy Benefit Manager 1Q 2022 P&T Part D Actions**

Dr. Huynh reviewed the Pharmacy Benefit Manager 1Q 2022 P&T Part D Actions.

**It was moved, seconded and the PBM Minutes and Actions were unanimously approved.**

**Motion:** Dr. Nakahira

**Second:** Dr. Parashar-Rokicki

**Ayes:** Dr. Alkoraishi, Dr. Huynh, Dr. Lin, Dr. Nakahira, Dr. Ngo, Dr. Parashar-Rokicki

**Absent:** Dr. Cung, Dr. Goel, Dr. Nguyen

**c. 2022 Update & 2023 Medical Benefit Drug Prior Authorization Grid**

Dr. Huynh reviewed the 2022 Update & 2023 Medical Benefit Drug Prior Authorization Grid.

**It was moved, seconded and the 2022 Update & 2023 Medical Benefit Drug PA Grid was unanimously approved.**

**Motion:** Dr. Nakahira

**Second:** Dr. Huynh

**Ayes:** Dr. Alkoraishi, Dr. Huynh, Dr. Lin, Dr. Nakahira, Dr. Ngo, Dr. Parashar-Rokicki

**Absent:** Dr. Cung, Dr. Goel, Dr. Nguyen

**d. Diabetic Supplies Criteria**

Dr. Nguyen reviewed the Diabetic Supplies Criteria.

**It was moved, seconded and the Diabetic Supplies Criteria was unanimously approved.**

**Motion:** Dr. Nakahira

**Second:** Dr. Huynh

**Ayes:** Dr. Alkoraishi, Dr. Huynh, Dr. Lin, Dr. Nakahira, Dr. Ngo, Dr. Parashar-Rokicki

**Absent:** Dr. Cung, Dr. Goel, Dr. Nguyen

**8. Discussion of SCFHP Pharmacy Clinical Programs**

**a. Diabetes Management Program - Updates**

Dr. Tambe reviewed the Diabetes Management (DM) Program and provided updates.

**b. Pharmacy Clinical Program FY2023 Planning**

Dr. Tambe reviewed the Pharmacy Clinical Program FY2023 Planning.

**9. New Drugs and Class Reviews**

**a. COVID-19 Updates**

Dr. Tambe reviewed the COVID-19 updates.

**b. Tirzepatide – Type 2 Diabetes**

Dr. Tambe reviewed Tirzepatide, which is a first in its class for Type 2 diabetes.

**c. Vonoprazan - H. Pylori**

Dr. Jennifer Ko, Pharmacy Resident, reviewed the medication Vonoprazan.

**d. Tapinarof – Plaque Psoriasis**

Dr. Ko reviewed the medication Tapinarof.

**e. Mavacamten – Obstructive Hypertrophic Cardiomyopathy**

Dr. Ko reviewed the medication Mavacamten.

**f. Informational Only:**

- i) Amyotrophic Lateral Sclerosis (ALS)
- ii) Tebipenem – UTI and pyelonephritis
- iii) Rinvoq and Skyrizi – Inflammatory Bowel Disease
- iv) Myfembree – Endometriosis
- v) Jardiance – Heart Failure with Preserved Ejection Fraction
- vi) Fintepla – Lennox Gastaut Syndrome (LGS)

**g. New and generic pipeline**

Dr. Huynh reviewed a presentation on the new pipeline agents.

***Reconvene in Open Session at 7:34 p.m.***

**10. Adjournment**

The meeting adjourned at 7:35 p.m. The next P&T Committee meeting will be on Thursday, September 15, 2022.

---

Jimmy Lin, MD, Chair

---

Date